These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs]. Author: Sakura H, Togashi M, Iwamoto Y. Journal: Nihon Rinsho; 2002 Jan; 60(1):123-9. PubMed ID: 11808322. Abstract: Beta 3-adrenergic receptors are expressed mainly in adipose tissues and play an important role in lipolysis and thermogenesis. Chronic administration of beta 3-adrenergic receptor agonists into obese rodents reduce the size of adipocytes by the breakdown of triglyceride and ameliorate insulin resistance associated with the normalization of the expression of adipocytokines, such as leptin and tumor necrosis factor-alpha. However, acute administration of the drugs induce remarkable insulin secretion, the mechanism of which is still unclear. Although the effect of beta 3-adrenergic receptor agonists may be different between rodents and human, these drugs are promising as anti-obese or anti-diabetic agents, and several clinical studies are underway.[Abstract] [Full Text] [Related] [New Search]